CHAARTED: ADT Plus Docetaxel in Prostate Cancer
Dr. Morris discusses results and implications of the CHAARTED trial, which studied the survival impact of androgen deprivation therapy (ADT) plus docetaxel vs ADT alone for hormone-sensitive newly metastatic prostate cancer.
Michael J. Morris, MD, member of the medical oncology and genitourinary oncology services at Memorial Sloan Kettering Cancer Center, was a discussant on the ECOG-led phase III randomized CHAARTED trial that studied the survival impact of androgen deprivation therapy (ADT) plus docetaxel vs ADT alone for hormone-sensitive newly metastatic prostate cancer.
Dr. Morris talks about side effects seen during the trial, what accounted for the increase in the time to development of castration resistance seen, as well as what he thinks the effect will be if results of the FIRSTANA trial show cabazitaxel to be superior to docetaxel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer.
